Zevra Therapeutics (ZVRA) Capital Leases (2014 - 2018)

Zevra Therapeutics has reported Capital Leases for 5 years, with the latest figure at $396000.0 in Q4 2018.

• For the quarter ending Q4 2018, Capital Leases fell 29.54% year-over-year to $396000.0; the trailing twelve-month figure through Dec 2018 stood at $396000.0 (down 29.54% YoY), and the FY2018 full-year result was $396000.0, down 29.54% from the prior year.
• Capital Leases for Q4 2018 stood at $396000.0, down from $451000.0 in the prior quarter.
• The five-year high for Capital Leases was $657000.0 in Q4 2016, with the low at $3000.0 in Q3 2015.
• Historically, Capital Leases has averaged $310500.0 across 5 years, with a median of $423500.0 in 2018.
• Annual changes were most pronounced in 2017 — Capital Leases declined 14.46% — and 2018, when it slipped 29.54%.
• Zevra Therapeutics' Capital Leases stood at $26000.0 in 2014, then sank by 88.46% to $3000.0 in 2015, then surged by 21800.0% to $657000.0 in 2016, then dropped by 14.46% to $562000.0 in 2017, then decreased by 29.54% to $396000.0 in 2018.
• The last three Capital Leases figures came in at $396000.0 (Q4 2018), $451000.0 (Q3 2018), and $466000.0 (Q2 2018), per Business Quant data.